GSK partners with LSMDA to end malaria for good

Malaria has a high prevalence in Sub-Saharan

Africa and is a major public health problem in

Nigeria. It accounts for over 60% outpatient

visits and 30% hospital admissions. The disease

has negatively impacted the Nigerian economy

with billions of Naira lost to it as cost of

treatment and loss in man-hours. No wonder

GlaxoSmithKline Nigeria partnered with the

Lagos State Medicine Dealers Association

(LSMDA) to join the fight to help end Malaria for

good.

To mark this year’s World Malaria Day, the two

organizations came together at the National

Stadium, Surulere, Lagos, to commemorate the

2016 World Malaria Day, and to reaffirm Colart

and Panadol as an effective and rational

combination medication to treat the disease and

relieve patients of pains and fever associated

with malaria.

Colart, an antimalarial, and Panadol, an

analgesic, are medicines produced by GSK, one

of the world’s leading research-based

pharmaceutical and healthcare companies,

renowned for producing quality medicines.

Speaking at the event which drew Medicine

Dealers from far and near, the Marketing

Director for GSK Consumer Health, Kerry

Alexander, said,

“Malaria is a huge burden in Africa,

with more than 500,000 deaths every

year. GSK is joining the campaign to ‘End

Malaria for Good’ with two of its

products: Colart, an anti-malarial that

kills the malaria parasite, and Panadol,

an analgesic that helps treat symptoms

associated with pain and fever. This

allows patients to feel better whilst they

get better.”

She further reaffirmed GSK’s commitment to

eradicate Malaria in Nigeria, in that, for over

40 years, GSK has continued to impact society,

improve the quality of human lives of the

Nigerian people by enabling them ‘to do more,

feel better and live longer’.